Breast cancer and ATM mutations: treatment implications

Hereditary Cancer in Clinical Practice · Published 2024-11-14 · DOI 10.1186/s13053-024-00300-9

Authors being retrieved — see the publisher record. https://doi.org/10.1186/s13053-024-00300-9

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Implementation and Audit of Mainstream Genetic Testing Within a High‐Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion · The Breast Journal · 2026 · Cites or is cited by this article
• Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study · Hereditary Cancer in Clinical Practice · 2024 · Same journal
• Awareness of hereditary breast cancer and readiness for genetic testing among newly diagnosed patients with breast cancer in Nigeria: a multicentre study · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Meeting abstracts from the Annual Conference “Clinical Genetics of Cancer 2023” · Hereditary Cancer in Clinical Practice · 2024 · Same journal
• Tumour mutational burden using a targeted panel approach for comprehensive tumour profiling focusing on colorectal cancer · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Primary and metastatic brain tumours in hereditary cancer syndromes: case reports with and literature review · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• Clinical characteristics and healthcare burden of neurofibromatosis type 1 in Saudi Arabia: a single centre experience · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Genomic profiling in Bulgarian women with ovarian cancer: a dual-sample NGS approach · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer · Hereditary Cancer in Clinical Practice · 2026 · Same journal